Answers are grounded in this paper and cite their sources.
Oxidative stress has traditionally been viewed as an imbalance between reactive oxygen species (ROS) production and antioxidant defenses, leading to cellular damage and disease progression. However, the failure of conventional antioxidant therapies in many clinical settings has challenged the simplistic notion that indiscriminate ROS scavenging is therapeutically beneficial. Emerging evidence indicates that ROS act as essential signaling molecules involved in cellular homeostasis, immune responses, and adaptation to stress. Consequently, contemporary pharmacological strategies are shifting from global antioxidant supplementation toward selective modulation of redox signaling pathways. This paradigm, herein referred to as Redox Precision Pharmacology, focuses on targeting specific redox-sensitive molecular nodes, including the Nrf2/Keap1 axis, NADPH oxidases (NOXs), mitochondrial ROS sources, and ferroptosis-related pathways. Ferroptosis, an iron-dependent form of regulated cell death characterized by lipid peroxidation, has emerged as a particularly promising therapeutic target in oncology, neurodegeneration, and ischemia–reperfusion injury. This review discusses the evolution of redox-based therapeutics, examines current pharmacological approaches targeting redox signaling networks, and explores future opportunities for precision medicine based on redox biomarkers and ferroptosis susceptibility. The RPF is proposed as an unvalidated, disease-specific research framework; approved indication-specific therapies are distinguished from investigational and preclinical approaches. Clinical utility requires analytical qualification, independent predictive validation, and prospective treatment-selection trials.
No takes yet. Share an insight, caveat, or question.
Federica Mannino (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: